Division of Medical Oncology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA. adjei.alex@mayo.edu
Lung cancer (Amsterdam, Netherlands) 2001 DecPemetrexed disodium (ALIMTA) is a novel antimetabolite that inhibits at least three folate-dependent enzymes, thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase. Pemetrexed disodium is broadly active in a wide variety of solid tumours, including non-small cell lung, breast, bladder, head and neck and ovarian cancers. Gemcitabine is a broadly active pyrimidine nucleoside antimetabolite, which is approved for the treatment of pancreatic and non-small cell lung cancers. Three preclinical studies have been reported that show cytotoxic synergy between gemcitabine and pemetrexed. Clinical activity with this combination has been observed in a phase I study, with partial responses in three of five patients previously treated for non-small cell lung cancer. An international phase II study of this combination in non-small cell lung cancer is ongoing.
A A Adjei. Gemcitabine and pemetrexed disodium combinations in vitro and in vivo. Lung cancer (Amsterdam, Netherlands). 2001 Dec;34 Suppl 4:S103-5
PMID: 11742712
View Full Text